2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4538 Longitudinal trajectories of patient-reported and clinician-assessed frailty across lines of therapy for multiple myeloma: Agreement between frailty instruments and associations with health-related quality of life

Kaylee Timlin, MSN, APRN, Diana Abbott, PhD2, Gianni Solis, BS, PSM, CCMA3, Kelly Sidor, ACNP-BC, APN4, Kristin Burkett, MSN, NP5, Erin Fahey-Harrison, MS, PA-C6, Tracy Farrell, PA-C7, Alex Hirose, PA-C, MMS8, Alleson Ida, DNP9, Kathleen Logan, MMSc, PA-C10, Caroline Pearson, NP, MSN11, Lauren Petronella, PA-C12, Glen Peterson, DNP, ACNP13, Theodore Simos, PA-C14, Kelsey J Watson, MSN, AGNP-C15, Kaitlyn Hoover, MS16, Jennifer K Tobin, PharmD17, Hillary Lum, MD, PhD18, Elizabeth R Kessler, MD19, Jorge Monge, MD20, Daniel W. Sherbenou, MD, PhD21, Ajay Major, MD, MBA22
1 University of Colorado School of Medicine, Aurora, Colorado, United States
2 Colorado School of Public Health, Aurora, Colorado, United States
3 University of Colorado School of Medicine, Aurora, Colorado, United States
4 University of Colorado School of Medicine, Aurora, Colorado, United States
5 University of Colorado School of Medicine, Aurora, Colorado, United States
6 University of Colorado School of Medicine, Aurora, Colorado, United States
7 University of Colorado School of Medicine, Aurora, Colorado, United States
8 University of Colorado School of Medicine, Aurora, Colorado, United States
9 University of Colorado School of Medicine, Aurora, Colorado, United States
10 University of Colorado School of Medicine, Aurora, Colorado, United States
11 University of Colorado School of Medicine, Aurora, Colorado, United States
12 University of Colorado School of Medicine, Aurora, Colorado, United States
13 University of Colorado School of Medicine, Aurora, Colorado, United States
14 University of Colorado School of Medicine, Aurora, Colorado, United States
15 University of Colorado School of Medicine, Aurora, Colorado, United States
16 University of Colorado School of Medicine, Aurora, Colorado, United States
17 University of Colorado School of Medicine, Aurora, Colorado, United States
18 University of Colorado School of Medicine, Aurora, Colorado, United States
19 University of Colorado School of Medicine, Aurora, Colorado, United States
20 University of Colorado School of Medicine, Aurora, Colorado, United States
21 University of Colorado School of Medicine, Aurora, Colorado, United States
22 University of Colorado School of Medicine, Aurora, Colorado, United States

Background

Frailty predicts treatment tolerability and outcomes in multiple myeloma (MM), but routine assessment remains challenging. The International Myeloma Working Group Frailty Score (IMWG FS) is an established frailty tool but is relatively burdensome to complete, whereas the brief Geriatric 8 (G8) may more easily screen for vulnerability domains which change over time. To facilitate routine implementation, we evaluated an entirely patient-reported G8 (ProG8) against the standard clinician-assessed G8 (ClinG8) and IMWG FS and explored associations with health-related quality of life (HRQoL). 

Methods

Adults with MM were enrolled in a prospective longitudinal study in 3 cohorts: newly diagnosed, undergoing cellular therapy, and initiating new lines of therapy for relapsed/refractory (R/R) MM. ProG8, ClinG8, IMWG FS, and HRQoL instruments (PROMIS Global Health-10 and Cognitive Function 4a) were collected at baseline, 3 months, and 6 months in English and Spanish. Risk for frailty was defined as G8 score ≤14 and IMWG FS ≥2. Agreement between frailty instruments was assessed using percent agreement, Cohen’s kappa (k), and McNemar tests at each timepoint and within each cohort. Exploratory associations between ProG8 frailty and selected HRQoL measures were assessed. 

Results

The interim cohort included 78 patients: 17 newly diagnosed, 48 cellular therapy, and 13 R/R MM. Median age was 67 years (IQR, 60-74), 54% male, 80% White, 12% Black, 13% Hispanic, and 77% with comorbidities. Age differed among study cohorts (median 70, 63, and 75 years, respectively; p=0.01), without differences in sex, comorbidity, cytogenetics, or disease stage. 

Frailty classification differed substantially by instrument. At baseline, ProG8 classified 59/78 (76%), ClinG8 classified 48/78 (62%), and IMWG FS classified 10/78 (13%) as frail. This pattern persisted at follow-up timepoints: 50/65 (77%), 52/66 (79%), and 11/66 (17%) at 3 months and 36/50 (72%), 36/52 (69%), and 6/52 (12%) at 6 months. 

ProG8 and ClinG8 agreement was moderate at baseline (k=0.62; 95% CI, 0.44-0.80) and 3 months (k=0.60; 95% CI, 0.37-0.84), but lower at 6 months (k=0.33; 95% CI, 0.05-0.61). At baseline, 12 patients were ClinG8-fit/ProG8-frail, compared with 1 ClinG8-frail/ProG8-fit (McNemar p=0.002). ProG8/ClinG8 agreement was 65% (k=0.31) in newly diagnosed, 85% (k=0.68) in cellular therapy, and 100% (k=1.00) in R/R MM cohorts at baseline. Discordance was predominantly ProG8-frail/ClinG8-fit (12/13 cases) with G8 item-level discrepancies most frequent for medication burden, reduced food intake, and weight loss. 

Conversely, agreement with IMWG FS was minimal for ProG8 (k=0.05, -0.07, and 0.02) and ClinG8 (k=0.08, 0.01, and 0.11) at baseline, 3, and 6 months, respectively (McNemar p<0.0001). However, among 10 patients who were IMWG FS-frail at baseline, 9 were ProG8-frail, 8 were ClinG8-frail, and 8 were frail by both G8 measures. Sankey plots showed bidirectional fit/frail transitions for both G8 measures, whereas IMWG classifications remained predominantly fit/non-frail and comparatively stable across follow-up. 

ProG8-frail patients had worse mean PROMIS Mental Health (44 vs 54; p=0.003) and Physical Health scores (35 vs 45; p=0.001) than fit patients at baseline. At 3 months, ProG8 frailty was associated with worse Physical Health (39 vs 50; p=0.003) and Cognitive Function scores (42 vs 48; p=0.027). Within the cellular therapy cohort, ProG8-frail patients had worse Physical Health (35 vs 42; p=0.038) at baseline and worse Mental Health (47 vs 55; p=0.024), Physical Health (39 vs 53; p=0.003), and Cognitive Function scores (41 vs 51; p=0.025) at 3 months than ProG8-fit patients. 

Conclusions 

ProG8 and standard ClinG8 identified more patients with risk of frailty than the IMWG FS across MM lines of therapy and demonstrated greater concordance with each other than with the IMWG FS. Importantly, ProG8 captured nearly all patients with IMWG-defined frailty at baseline, suggesting that G8-based assessments may identify broader vulnerability domains and dynamic changes over time, particularly in the MM immunotherapy era. Associations between ProG8 frailty risk and worse mental, physical, and cognitive HRQoL support further validation of the ProG8 as a scalable, patient-centered approach to longitudinal frailty measurement in MM. Survival outcomes and MM-specific HRQoL will be evaluated in future analyses.

Kaylee Timlin, MSN, APRN: No relevant conflicts of interest to declare.